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Introduction. Cushing’s syndrome (CS) is a clinical condition characterized by excessive cortisol production, associated with
metabolic complications, such as diabetes mellitus, dyslipidemia, metabolic syndrome, hypertension, and cardiovascular
diseases. Nowadays, the occurrence of autoimmune diseases in CS have not been completely evaluated in the previous
studies. Objective. The aim of this study was to evaluate the occurrence of autoimmune diseases in CS patients after
successfully treated. Materials and Methods. From January 2001 to December 2017, in our Secondary Hypertension Unit,
we evaluated 147 CS patients (91 with ACTH-independent disease, 54 with ACTH-dependent disease, and 2 patients with
ectopic ACTH production. Results. 109 CS patients (74.1%) were surgically treated (67 ACTH-independent CS patients
(61.5%) undergone adrenalectomy and 42 ACTH-dependent CS (38.5%) undergone transsphenoidal surgery) and evaluated
after 6, 12, and 24 months after clinical and biochemical remission of disease. In 9 (8.3%) of overall treated CS patients
(8.3%), during follow-up, we observed the onset of some manifestations of autoimmune diseases. In particular, one patient
had a systemic lupus erythematosus, one patient had rheumatoid arthritis, 4 patients reported autoimmune thyroiditis
(Basedow-Graves’ disease and Hashimoto’s thyroiditis), one patient had clinical features of psoriasis, one patient showed
myasthenia gravis, and one patient had giant cell arteritis. Conclusions. Our results demonstrate that patients successfully
treated for CS could develop autoimmune diseases. Therefore, after treatment, CS patients need to be strictly monitored in
order to evaluate the possible onset of autoimmune diseases.
1. Introduction
Cushing’s syndrome (CS) is a rare endocrine disorder
characterized by prolonged, inappropriate excess of cortisol
secondary to endogenous or exogenous causes [1]. Exoge-
nous hypercortisolism is usually caused by prolonged admin-
istration of corticosteroids for chronic inflammatory
diseases. On the other hand, endogenous hypercortisolism
can be adrenocorticotropic (ACTH)-dependent or indipen-
dent [2]. Overall, ACTH-dependent forms account for about
60–85% of cases, and of these, 80% are due to pituitary
adenomas, whereas the remaining 20% are related to ectopic
ACTH production. ACTH-independent CS is mostly due to
adrenal tumors (adenoma in 60% and carcinoma in 40% of
cases) [1]. The mainly described clinical features of CS are
facial plethora, rounded face, decreased libido, thin skin,
decrease linear growth in children, menstrual irregularity,
glucose intolerance, hirsutism, easy bruising, osteoporosis,
hypertension, and depression/emotional lability [3–5]. In
addition, hypercortisolism is also characterized by its inhibi-
tory function on immune system in humans [6]. In fact, sev-
eral evidences shown that excess of cortisol production
determines the involution of lymphoid tissue mass and lym-
phopenia with an increased susceptibility to infections [7].
The restoration of physiological production of cortisol can
be associated to immune reaction, leading to the onset of
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autoimmune diseases [8]. In the literature, after hypercor-
tisolism remission in CS patients, some case reports
reported the onset of autoimmune diseases, such as Hashi-
moto autoimmune thyroiditis and Graves’ disease [9]. In par-
ticular, the evidence on the development of autoimmune
manifestations after surgical resolution of hypercortisolism
is not well described and focused in clinical practice.
The aim of our study was to evaluate the occurrence of
some newly secondary diagnosed autoimmune diseases in
patients with CS after successful treatment.
2. Materials and Methods
From January 2001 to December 2017, we have retrospec-
tively evaluated 147 CS patients (38 male (26%), 109 female
(74%), mean age 52 years), referred to our Secondary Hyper-
tension Unit, University of Rome “Sapienza,” Italy. Informed
consent was obtained from all subjects. Of these 147 cases, 91
(61.9%) patients had an ACTH-independent CS, 54 (36.7%)
patients were affected by an ACTH-dependent CS, and 2
(1.3%) patients with CS due to ectopic ACTH production.
In all groups, 66.6% CS patients underwent surgical
treatment (67 (61.5%) patients with ACTH-independent
syndrome underwent laparoscopic adrenalectomy and 42
(38.5%) patients with ACTH-dependent disease underwent
transsphenoidal hypophyseal microneurosurgery), showing
complete remission of cortisol excess based on the nor-
malization of biochemical and clinical features during
follow-up.
2.1. Cushing’s Syndrome Diagnosis. The CS diagnosis was
based on the clinical signs and symptoms (central redistribu-
tion of fat, hypertension, osteoporosis, and muscle weak-
ness), hormonal data, and imaging tests (pituitary magnetic
resonance imaging (MRI), adrenal computed tomography
(CT), and adrenal scintiscan). Endocrine tests for CS showed
a lack of diurnal rhythm of plasma cortisol (PC) levels
(>138nmol/L or >5μg/dL at midnight), no suppression of
the PC levels (>50 nmol/L or >1.8μg/dL) after overnight
1mg dexamethasone suppression test (DXM), and increased
24-hour urinary free cortisol (UFC) excretion (> 270nmol/
24 h or > 100μg/24 h). Measurement of plasma ACTH dif-
ferentiated ACTH-dependent CS (ACTH≥ 10pg/mL) from
ACTH-independent CS (< 10pg/mL). ACTH was measured
with the radioimmunoassay method (RIA), normal limit
10–90pg/mL and inter/intra-assay CV 8.3/6.2, respectively;
PC was measured with the radioimmunoassay method
(RIA), normal limit 9.6–26μg/dL and inter/intra-assay CV
5.5/4.5, respectively; 24h urinary free cortisol was measured
with the radioimmunoassay method (RIA), normal limit
1.37–7.53μg/24 h and inter/intra-assay CV 5.5/4.5, respec-
tively. For ectopic ACTH-dependent differential diagnosis,
patients underwent desmopressin test, corticotropin-
releasing hormone (CRH) test, and inferior petrosal sinus
sampling (IPSS) with desmopressin stimulus indicated
when MRI was negative for a pituitary lesion; some
patients with initial occult tumors underwent octreotide
imaging (octreoscan) [10].
3. Results
After surgical removal of hypercortisolism, overall CS
patients have been evaluated at 6, 12, and 24-month. During
follow-up, nine out of them (8.25%) showed the onset of
symptoms and signs of autoimmune diseases, previously
not manifested (Table 1). Average time of clinical manifesta-
tion was 8.4 months, ranging from 4 up to 24 months. The
ratio of female to male patients was 8 : 1. In particular, the
autoimmune diseases were 1 patient with rheumatoid arthri-
tis, 1 patient with systemic lupus erythematosus (SLE), 4
patients (3 women and 1 man) with autoimmune thyroid
diseases, 1 patient with psoriasis, 1 patient with myasthenia
gravis, and, finally, 1 patient with giant cell arteritis.
In Table 2, we reported the demographic, anthropomet-
ric, hemodynamic, biohumoral, and hormonal parameters
of overall patients evaluated and the distinction of the
two groups in relation to the development of autoimmune
disease after surgical treatment (group A: patients without
development of autoimmune disease; group B: patients
with development of autoimmune disease).
Group A showed older age compared to group B (61.0
± 11.7 yrs vs. 52.3± 12.7 yrs, p < 0 03).
Table 1: Etiology of Cushing’s syndrome (CS), histology of endocrine disease, and immune disease in patients with treated CS and newly
onset of autoimmune disease.
Case report Sex Etiology Histology Immune disease
1 F AD Pituitary adenoma Graves’ disease
2 F AD Pituitary adenoma Hashimoto thyroiditis
3 F AI Adrenal adenoma Psoriasis
4 F AI Adrenal adenoma Graves’ disease
5 F AI Adrenal hyperplasia Systemic lupus erythematosus
6 M AI Adrenal hyperplasia Hashimoto thyroiditis
7 F AD Pituitary μ-adenoma Rheumatoid arthritis
8 F AI Adrenal adenoma Myasthenia gravis
9 F AI Adrenal adenoma Horton disease
M: male; F: female; AD: ACTH-dependent; AI: ACTH-independent.
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Interestingly, at baseline, we found that group B showed
significantly higher levels of PC and 24h-UFC compared to
group A (818.1± 245.0 nmol/L vs. 459.5± 161.1 nmol/L, p <
0 001, and 514.5± 173.8 nmol/24 h vs. 249.4± 175.2 nmol/
24 h, p < 0 001, respectively) and higher levels of PC after
the DXM test (260.8± 158.8 nmol/L vs. 109.7± 82.7 nmol/L,
p < 0 001). Regarding other biochemical parameters, in
group B, we found significantly higher levels of total choles-
terol (245.2± 42.5mg/dL vs. 203.2± 39.9mg/dL, p < 0 01),
LDL cholesterol (150.5± 29.7mg/dL vs. 121.5± 36.6mg/dL,
p < 0 01), and triglycerides (245.2± 42.5mg/dL vs. 203.2±
39.9mg/dL, p < 0 01) compared to group A.
None hormonal and biochemical differences were
observed between two groups during follow-up. In both
groups, compared to baseline evaluation, after hypercorti-
solism resolution we found a significant reduction of office
systolic blood pressure (SBP) (group A 143± 20mmHg vs.
137± 17mmHg, p < 0 01; group B 146± 14mmHg vs. 123
± 19mmHg, p < 0 01), office diastolic blood pressure
(DBP) (group A 85± 12mmHg vs. 82± 11mmHg, p <
0 01; group B 93± 13mmHg vs. 79± 13mmHg, p < 0 02),
and LDL cholesterol (group A 121.5± 36.6mg/dL vs.
111.9± 33.9mg/dL, p < 0 03; group B 150.5± 29.7mg/dL
vs. 116.0± 36.2mg/dL, p < 0 02). Moreover, during follow-
up, in group B, we have seen significant reduction of waist
circumference compared to baseline (102.8± 8.7 cm vs.
90.8± 10.8 cm, p < 0 01) and total cholesterol (245.2±
42.5mg/dL vs. 199.9± 30.0mg/dL, p < 0 01).
4. Case Reports
4.1. Patient 1. In 2008, a 44-year-old woman was referred to
our Unit for high blood pressure, moon face, excess hair
growth, easy bruising, headache, and weight gain. She had a
family history of diabetes type 2. The diagnosis of ACTH-
dependent CS was confirmed by high serum cortisol with a
lack of circadian rhythm and high serum ACTH. MRI
showed a pituitary microadenoma. In June 2008, she under-
went transsphenoidal surgery and the histological examina-
tion confirmed a basophil adenoma. Six months later,
clinical and biochemical signs of cortisol excess significantly
improved. Subsequently, in January 2009, patient reported
fatigue, palpitations, and exophthalmos. A thyroid ultra-
sound showed whole increase of the gland. FT4 and FT3
levels and TSH receptor antibodies were high, whereas TSH
was suppressed, suggesting diagnosis of Graves’ disease.
Patients underwent treatment with propranolol 40mg/day
Table 2: Demographic, anthropometric, hemodynamic, biochemical, and hormonal parameters at baseline and after a 24-month follow-up
in patients with treated Cushing’s syndrome (CS) compared with the group of Cushing’s syndrome patients with posttreatment onset of
autoimmune diseases (CS with AD).
Baseline 24-month FU p
CS (n = 100) A CS with AD (n = 9) B p CS (n = 100) C CS with AD (n = 9) D p A vs. C B vs. D
Age (years) 61 0 ± 11 7 52 3 ± 12 7 0.03 63 1 ± 11 5 54 2 ± 12 8 0.03 ns ns
Sex (M/F) 63/37 1/9 63/37 1/9
BMI (kg/m2) 27 5 ± 4 6 29 2 ± 4 4 ns 27 5 ± 3 9 25 8 ± 5 6 ns ns ns
WC (cm) 98 4 ± 12 3 102 8 ± 8 7 ns 98 4 ± 14 5 90 8 ± 10 8 ns ns 0.01
Office SBP (mmHg) 143 ± 20 146 ± 14 ns 137 ± 17 123 ± 19 ns 0.01 0.01
Office DBP (mmHg) 85 ± 12 93 ± 13 ns 82 ± 11 79 ± 13 ns 0.01 0.02
HR (bpm) 67 ± 12 75 ± 8 ns 66 ± 9 68 ± 14 ns ns ns
Creatinine (mg/dL) 0.84± 0.4 1.05± 1.06 ns 0.95± 0.35 1.19± 1.24 ns ns ns
Na+ (mmol/L) 142 9 ± 3 2 142 7 ± 2 4 ns 143 1 ± 2 6 141 4 ± 2 1 ns ns ns
K+ (mmol/L) 4 4 ± 0 5 3 9 ± 1 4 ns 4 4 ± 0 4 4 3 ± 0 2 ns ns ns
Calcium (mg/dL) 9 6 ± 0 5 9 0 ± 0 2 ns 9 6 ± 0 4 8 9 ± 0 4 ns ns ns
FG (mg/dL) 96 ± 24 92 ± 10 ns 96 ± 23 84 ± 16 ns ns ns
Uric acid (mg/dL) 5 2 ± 1 5 5 6 ± 1 1 ns 5 1 ± 1 3 5 5 ± 1 4 ns ns ns
TC (mg/dL) 203 2 ± 39 9 245 2 ± 42 5 0.01 196 7 ± 41 8 199 9 ± 30 0 ns ns 0.01
HDL-C (mg/dL) 58 1 ± 17 4 51 8 ± 11 9 ns 61 2 ± 40 4 60 8 ± 15 9 ns ns ns
LDL-C (mg/dL) 121 5 ± 36 6 150 5 ± 29 7 0.01 111 9 ± 33 9 116 0 ± 36 2 ns 0.03 0.02
TGL (mg/dL) 113 4 ± 48 5 185 9 ± 112 8 0.01 124 9 ± 56 9 153 4 ± 112 3 ns ns ns
UFC (nmol/24 h) 249 4 ± 174 2 514 5 ± 173 8 0.001 155 2 ± 92 4 138 8 ± 83 5 ns 0.001 0.001
PC (nmol/L) 459 5 ± 160 3 818 1 ± 231 0 0.001 418 0 ± 118 0 373 5 ± 96 9 ns 0.05 0.001
PC DXM (nmol/L) 109 7 ± 82 7 260 8 ± 158 8 0.001 86 0 ± 25 1 40 0 ± 11 1 0.001 0.001 0.001
BMI: body mass index; WC: waist circumference; SBP: systolic blood pressure; DBP: diastolic blood pressure; HR: heart rate; Na+: serum sodium; K+: serum
potassium; FG: fasting serum glucose; TC: total cholesterol; HDL-C: HDL cholesterol; LDL-C: LDL cholesterol; TGL: triglycerides; UFC: urinary free
cortisol; PC: plasma cortisol; PC DXM: plasma cortisol postovernight 1 mg dexamethasone test.
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and methimazole 15mg/day, obtaining an acceptable control
of the disease.
4.2. Patient 2. The second case was a 48-year-old woman
referred for hypertension, moon face, buffalo hump, severe
muscle wasting, and hair grown on the face. The diagnosis
of ACTH-dependent CS was confirmed by hormonal analy-
sis, and MRI detected a pituitary adenoma. She underwent
transsphenoidal surgery in May 2007, and the histological
examination confirmed microadenoma. Three months after
surgery, her blood pressure and both PC and ACTH levels
were normal.
However, after 8 months, she reported weakness and
weight gain. The evaluation of thyroid function showed low
FT4, TSH of 1.3mIU/L, and positive TPO Ab (212 IU/mL,
n.v. 1–50 IU/mL). Ultrasound imaging of the thyroid gland
revealed a diffuse dyshomogeneous pattern, suggesting diag-
nosis of Hashimoto thyroiditis. She started therapy with
levothyroxine 50mcg once a day with clinical improvement.
4.3. Patient 3. In May 2013, a 52-year-old woman was
referred with cortisol excess confirmed by high 24h-UFC
values and an overnight 1mg DXM test, bilateral adrenal
gland lesions (right 26mm; left 24mm), and scintigraphic
evidence of increased radionucleotide uptake by the left adre-
nal gland. The patient underwent left adrenalectomy, and
histological evaluation confirmed an adrenal adenoma. Dur-
ing follow-up, both PC and 24h-UFC values were normal. In
December 2013, she developed a skin disorder characterized
by reddish or salmon-like, raised, scaly skin lesions in knees,
buttocks crease, and ears. A dermatologist confirmed the
psoriasis diagnosis and required a topical tacalcitol therapy.
4.4. Patient 4. A 38-year-old woman was diagnosed with CS,
due to a 27mm nodule of the right adrenal gland. She
underwent right adrenalectomy, and histological examina-
tion confirmed an adrenal adenoma. Five months after
biochemical and clinical resolution of hypercortisolism,
she developed tremor of the hands, sweating, insomnia,
weight loss, palpitations, anxiety, itch, and neck pain. Hyper-
thyroidism was suspected and confirmed by hormonal evalu-
ation (TSH suppressed with elevated free fraction of T3 and
T4 and the presence of anti-TSH receptor antibodies). Sub-
sequently, methimazole 5mg/day was administered with
clinical improvement.
4.5. Patient 5. In January 2010, a 36-year-old woman with
high blood pressure levels was evaluated in our specialized
Unit. Plasma aldosterone, plasma renin activity, and 24h uri-
nary metanephrines were normal. 24h-UFC excretion and
PC at 8 am were higher with nonsuppression by an overnight
1mg DXM test. MRI showed a left adrenal mass (40mm).
Three months later, left adrenalectomy was performed and
histological examination confirmed an adrenal adenoma.
Two years after, the patient reported onset of oral
aphthous ulceration in the hard palate, photosensitivity,
symmetric arthralgias on wrists, fibromyalgia, and cutaneous
vasculitis. Antinuclear antibodies (ANA) were positive, and
p-Anti-Neutrophil Cytoplasmic Antibodies (ANCA) and c-
ANCA were negative, confirming SLE. Hydroxychloroquine
200mg twice per day was prescribed with subsequent clinical
improvement.
4.6. Patient 6. A 45-year-old man was diagnosed with CS due
to a right adrenal gland lesion (60mm). Subsequently, the
patient underwent right adrenalectomy and histological
exam revealed multinodular hyperplasia of the adrenal gland.
Three months after surgery, both PC and 24h-UFC values
were normal and PC was suppressible by an overnight 1mg
DXM test. Nine months after surgery, he started to complain
fatigue, sensitivity to cold, weight gain and reduced appetite,
arthralgia, and myalgia. Thyroid function and antibodies
were investigated, with a final diagnosis of hypothyroidism
secondary to Hashimoto thyroiditis. Levothyroxine was
administered with clinical improvement.
4.7. Patient 7. In 2011, a 56-year-old woman presented to our
center reporting a high blood pressure level, fatigue, hir-
sutism, weight gain (body mass index 29 kg/cm2), and
buffalo hump. Laboratory tests showed high PC, not sup-
pressible after an overnight 1mg DXM test, and high
24h-UFC and plasma ACTH levels. The diagnosis of
ACTH-dependent CS was confirmed by MRI that showed
a small left mass in the adenohypophysis. In January
2012, she underwent transsphenoidal surgery and the his-
tological examination revealed a pituitary adenoma. Seven
months later, she began to suffer from myalgia, arthralgia
(shoulders, knees, wrists, and hands), headache, and long-
lasting morning stiffness. Afterwards, she reported insidious
swelling and pain of the first and second metacarpophalan-
geal (MCP) joints of the left hand. ANA were negative,
whereas rheumatoid factor (RF) and C-reactive protein
(CRP) were highly positive. Therefore, she was diagnosed a
rheumatoid arthritis. She started therapy taking methotrex-
ate once a week, folic acid 4mg twice a week, and methyl-
prednisolone 4mg/day.
4.8. Patient 8.A hypertensive 62-year-old woman was admit-
ted for the evaluation of an incidentally discovered right side
adrenal mass. CT scan shown a 7 cm mass in the right
adrenal gland, and after careful examination, the patient
was diagnosed with subclinical hypercortisolism (SH). Adre-
nalectomy was performed inMarch 2013, and histopatholog-
ical examination showed an adrenocortical adenoma.
Significant symptoms and signs appeared 5 months later
(bilateral ptosis, double vision, and proximal muscle weak-
ness in the arms bilaterally); during specific evaluation, chest
CT showed a solid tissue mass in the mediastinum. The diag-
nosis of myasthenia gravis was performed; thus, patient
started on pyridostigmine 180mg/day and prednisone
25mg/day, with no evident benefit. Subsequently, she under-
went a sternotomywith excision of the tumor, which histolog-
ically proved to be a type 2B thymoma. During the 1-year
follow-up in our Unit, patient reported complete regression
ofmyasthenic symptoms, with normal electrodiagnostic tests.
She remained well on pyridostigmine 120mg/day and antihy-
pertensive therapy (amlodipine and bisoprolol) with good
control of blood pressure [11].
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4.9. Patient 9. A hypertensive 61-year-old woman with a
right adrenal incidentaloma was studied in our specialized
Unit. Both PC (at 8 a.m.) and 24h-UFC values were higher
and not suppressible after an overnight 1mg DXM test, sug-
gesting CS diagnosis. In April 2013, she underwent right
adrenalectomy and histological evaluation confirmed an
adrenal adenoma. Four months later, she began to suffer
from fatigue, mild headaches, bilateral aching, and stiffness
of neck and shoulders. In September 2013, she went to emer-
gency room, for right vision loss and severe headache. Oph-
thalmoscopy showed pale and swollen optic disc, dilated
retinal veins, and several flame-shaped hemorrhages, such
as an anterior ischemic optic neuropathy (AION). Intrave-
nous methylprednisolone was administered. A cross-
sectional biopsy showed transmural inflammation with
mononuclear cells and giant cells infiltrating the media, com-
patible with temporal arteritis (Horton disease). After dis-
charge, prednisolone p.o. 25mg twice a day was
administered with significant clinical improvement.
5. Discussion
CS is caused by chronic hypercortisolism resulting in a char-
acteristic clinical phenotype and multisystem morbidity. The
phenotypic characteristics of CS are well described, such as
facial plethora, rounded face, decreased libido, thin skin,
menstrual irregularity, hypertension, hirsutism, depression/
emotional lability, glucose intolerance, weakness, and osteo-
porosis. Surgery is the treatment of choice for underlying
causes of hypercortisolism, and pharmacological therapy
has still a crucial role in inoperable patients [3–5].
Furthermore, it is known that in humans the inappropri-
ate endogen secretion or exogen administration of cortisol
may determine immunosuppression [12]. In fact, glucocorti-
coids (GCs) excess inhibits immune function by lymphoid
tissue involution and lymphopenia as well as increased
susceptibility to infections. On the other hand, GCs have a
pivotal role in the anti-inflammatory functions [13]. Cur-
rently, few studies showed a link between surgical or medical
resolution of endogenous hypercortisolism and the following
exacerbation or development of an autoimmune diseases.We
found in literature cases of exacerbating coeliac disease [14],
rheumatoid arthritis [15–17], sarcoidosis [18–20], SLE [21],
polymyalgia rheumatica [22], and thyroid diseases [9].
In a recent retrospective study, Tatsi et al. [23] studied a
pediatric cohort of 127 children with CS; from these, 10
children were diagnosed newly onset autoimmune diseases
after resolution of hypercortisolism (7.8% of prevalence). In
particular, the types of autoimmune disorders were coeliac
disease (no. 1), psoriasis (no. 1), Hashimoto thyroiditis
(no. 1), Graves’ disease (no. 1), optic neuritis (no. 2), skin
vitiligo (no. 2), allergic rhinitis/asthma (no. 1), and neu-
ropathy (no. 1).
Interestingly, it has been reported that patients with
autoimmune diseases, compared to healthy subjects, have
a reduced synthesis of GCs and altered CRP and corti-
sol/CRP ratio, in response to chronic inflammations such
as polymyalgia rheumatica and giant cell arteritis [24, 25].
On the other hand, the cross-sectional study of Agha-
Hosseini et al. [26] demonstrated that morning cortisol mea-
surements were significantly higher in patients with Hashi-
moto thyroiditis than healthy patients, suggesting that in
Hashimoto thyroiditis, cortisol excess (due to stress or spe-
cific disease) may downregulate hypothalamus and pituitary
sensitivity to GCs, with the activation of the HPA axis and
increased peripheral GC action. This pattern should lead to
significant immune function changes, from a T helper (Th)
1 to a Th2 cytokine profile shift. In conclusion, in some auto-
immune disease models, the Th2 immune response due to
GCs action may have a protective role [27].
We have surgically treated overall patients with laparo-
scopic adrenalectomy (anterior or posterior approach), as
suggested in literature [28, 29], with the absence of major
postoperative complications.
In our study, patients with CS who developed autoim-
mune diseases after successful treatment show higher levels
of PC (at rest and after the dexamethasone suppression
test) and 24h-UFC values compared to the group of patients
without autoimmune diseases, suggesting a possible trigger
to higher endogen cortisol hyperproduction by underlying
autoimmune disease, especially in patients affected by
ACTH-dependent CS (present in 33% in group B).
Therefore, we believe that physiological levels of GCs are
likely immunomodulatory rather than only immunosuppres-
sive, resulting in the shift of cytokines from a prevalent
proinflammatory to an anti-inflammatory pattern [30].
In our retrospective study, we evaluated 147 patients with
CS; 109 patients underwent surgical treatment with definitive
remission of excess of GCs and normalization of cortisol
levels, during follow-up, and 9 (8.25%) patients showed an
autoimmune disease. Most patients showed autoimmune
thyroid diseases (Graves’ disease and chronic Hashimoto
thyroiditis). This result agrees with the previous study by
Colao et al. that enrolled a series of patients with ACTH-
dependent CS, specifically evaluating thyroid function in
patients treated for CS, and showed increased risk of develop-
ing autoimmune thyroiditis after therapeutic resolution of
hypercortisolism, with rising positivity for specific antibodies
and occurrence of thyroiditis in 60% of treated patients [9].
The authors suggested an underlying abnormal immune
response, in particular in those patients who were genetically
disposed [10]. Therefore, the reduction of PC levels may
developed by an immune response shift, characterized by
increased levels of antithyroid antibodies [31]. Supporting
this hypothesis we presented the case of our patient with
myasthenia gravis (case No. 8) associated with positive
acetylcholine receptors antibodies and a type 2B thymoma
[11]. These clinical findings and our added reported cases
tend to prove how the suppressive effect of exceeding GCs
in CS modulates the immune system, with the possible
autoimmune disease arising as consequence of a specific
therapy [32].
In T cells, cortisol reduces the genetic expression of
interleukin (IL)-2 and suppresses the function of T cell
receptors and its downstream molecules (i.e., protein kinase
Scr, lymphocyte-specific protein tyrosine kinase, inositol
1,4,5-triphosphate), through membrane-bound receptors
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[33]. GCs reduce the production of cytokines, chemokines,
and arachidonic acid derivatives, the expression of Fcε
receptor I in mast cells, and the number of basophils and
histamine production [34]. Low GCs concentrations activate
macrophages (adhesion, chemotaxis, phagocytosis, and
cytokine production), while high concentrations have an
immunosuppressive effect [35].
Therefore, GCs excess certainly inhibits immune func-
tion. The improved GCs excess may, in several cases, restim-
ulate individual immunity, triggering autoimmune diseases.
Endocrine and immune systems influence each other
in a bidirectional fashion [36]. In fact, adrenal and sex
hormones, as well as vitamin D, melatonin, and prolactin
contribute importantly to the homeostasis of the immune
system. Indeed, some of the steroidal hormone activities
determine the inhibition or stimulation of immune sys-
tem components, in both physiological (suppression of
an unwanted response in pregnancy and stimulation of
a protective response in infections) and pathological
conditions.
Moreover, in the group of patients with the development
of autoimmune diseases after CS treatment, other than
higher levels of endogen overproduction of cortisol, we have
found higher levels of total cholesterol, LDL cholesterol, and
triglycerides, confirming the unfavorable metabolic effects of
hypercortisolism, especially on the lipid pattern [37]. It is
well described in literature that CS patients have higher
cardiovascular mortality and morbidity due to several meta-
bolic alterations, regarding glucose and lipid metabolism,
improved after CS treatment [38]. As regards lipid metabo-
lism, GCs can act through several mechanisms: increased
expression of adipose triglyceride lipase and hormone-
sensitive lipase (HSL) (involved in stored lipid breakdown
in mature adipocytes), increased lipolysis by the cAMP-
dependent activation of protein kinase A, impaired respon-
siveness to catecholamines and growth hormone (GH),
increased expression/activity of lipoprotein lipase, higher
neolipogenesis from substrates like glucose, and increased
ectopic storage of lipids in the liver and skeletal muscle
[37]. About it, in this study, the group of patients with
higher levels of PC at diagnosis showed more significant
reduction of waist circumference after resolution of
hyperticolism.
Further evaluations are needed to understand complexity
of the neuroendocrine network. We suggest to keep in mind,
in the clinical management of CS, that an autoimmune dis-
ease which is silent during the acute phase of hypercortiso-
lism may occur after the complete remission of the chronic
exposure to high PC levels [15, 21].
In conclusion, we strongly believe that after treatment of
CS, patients should be evaluated for the development of auto-
immune disorders in order to obtain an early diagnosis and a
proper treatment.
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